Aligos Therapeutics Inc (ALGS)

May 21, 2026

Cantor Fitzgerald Initiates Aligos Therapeutics(ALGS.US) With Buy Rating, Announces Target Price $20 - Moomoo

May 21, 2026

May 21, 2026

ALGS Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ov - GuruFocus

May 21, 2026

May 20, 2026

ALGS News | ALIGOS THERAPEUTICS INC (NASDAQ:ALGS) - ChartMill

May 20, 2026

May 15, 2026

Lawrence M. Blatt discloses 5.1% stake in Aligos Therapeutics (ALGS) - Stock Titan

May 15, 2026

May 15, 2026

Aligos (ALGS) Delivers Q1 2026 Beat — EPS $-2.21 vs $-2.27 ExpectedSocial Trade Signals - Newser

May 15, 2026

May 15, 2026

Woodline Partners reports 4.4% stake in Aligos Therapeutics (NASDAQ: ALGS) - Stock Titan

May 15, 2026

May 13, 2026

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at EASL Congress 2026 - Quiver Quantitative

May 13, 2026

May 13, 2026

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 - Weekly Voice

May 13, 2026

May 13, 2026

Liver disease drug data: Aligos secures 10 EASL 2026 slots - Stock Titan

May 13, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026

May 09, 2026

What you need to know before buying Aligos (ALGS) (Investor Concern) 2026-05-08Crowd Consensus Signals - newser.com

May 09, 2026

May 08, 2026

The operating leverage hidden in Aligos (ALGS) results | Q1 2026: EPS Exceeds ExpectationsTarget Revision - Newser

May 08, 2026

May 07, 2026

Aligos Therapeutics (NASDAQ:ALGS) Surges After Hours on Q1 Earnings Beat - ChartMill

May 07, 2026

May 07, 2026

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results - Investing News Network

May 07, 2026

May 07, 2026

China HBV license adds cash as Aligos (NASDAQ: ALGS) faces going‑concern risk - Stock Titan

May 07, 2026

May 07, 2026

Aligos lands FDA Fast Track and a $25M China deal for HBV drug - Stock Titan

May 07, 2026

May 07, 2026

Earnings Preview: ALGS to Report Financial Results Post-market on May 07 - Moomoo

May 07, 2026

May 07, 2026

How Aligos Therapeutics Inc. (ALGS) Affects Rotational Strategy Timing - Stock Traders Daily

May 07, 2026

May 05, 2026

Aligos Therapeutics Inc expected to post a loss of $2.22 a shareEarnings Preview - TradingView

May 05, 2026

Apr 30, 2026

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 - Investing News Network

Apr 30, 2026

Apr 30, 2026

Biotech Aligos will post first-quarter results after markets close May 7 - Stock Titan

Apr 30, 2026

Apr 29, 2026

[ARS] Aligos Therapeutics, Inc. SEC Filing - Stock Titan

Apr 29, 2026

Apr 29, 2026

Aligos Therapeutics says China pact puts HBV drug in focus amid trial updates - MSN

Apr 29, 2026

Apr 29, 2026

Aligos Therapeutics (Nasdaq: ALGS) details ESPP, auditor and pay votes - Stock Titan

Apr 29, 2026

Apr 28, 2026

Aligos’ licensing deal in China broadens trial scope, secures immediate $25m - MLex

Apr 28, 2026

Apr 27, 2026

Is Aligos (ALGS) overbought or oversold? (Drifts Higher) 2026-04-27Retail Flow - Newser

Apr 27, 2026

Apr 27, 2026

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Apr 27, 2026

Apr 27, 2026

This micro cap biotech stock is tracking its biggest intraday gains in 11 months – here’s why a China deal has retail buzzing - MSN

Apr 27, 2026

Apr 26, 2026

(ALGS) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Apr 26, 2026

Apr 24, 2026

Aligos Therapeutics (ALGS) Gets a Buy from H.C. Wainwright - The Globe and Mail

Apr 24, 2026

Apr 24, 2026

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network

Apr 24, 2026

Apr 24, 2026

New Aligos hires get stock options for 10,700 shares under Nasdaq rule - Stock Titan

Apr 24, 2026

Apr 23, 2026

Aligos Therapeutics jumps on China licensing agreement - MSN

Apr 23, 2026

Apr 23, 2026

Deal Watch: First Quarter Posted High Volume, Dollar Value In Alliance Deals - Citeline News & Insights

Apr 23, 2026

Apr 22, 2026

Aligos (ALGS) Stock: Why Margin Improvement (Institutional Demand) 2026-04-22Short Term Trading - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 22, 2026

Apr 21, 2026

Aligos Therapeutics Licenses Hepatitis B Drug Rights to Amoytop - TipRanks

Apr 21, 2026

Apr 21, 2026

Aligos Therapeutics (NASDAQ: ALGS) signs Hep B deal with up to $420M milestones - Stock Titan

Apr 21, 2026

Apr 20, 2026

Aligos (ALGS) Stock Volume Confirmation (Wavering) 2026-04-20Earnings Season - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

Apr 18, 2026

10 Health Care Stocks Moving In Friday's Intraday Session - Sahm

Apr 18, 2026

Apr 17, 2026

H.C. Wainwright reiterates Aligos stock rating on China deal - Investing.com UK

Apr 17, 2026

Apr 17, 2026

Aligos strikes license deal with Amoytop for HBV therapy development - The Pharma Letter

Apr 17, 2026

Apr 17, 2026

This drugmaker was about to run out of cash, but a Chinese partner came to the rescue - The Business Journals

Apr 17, 2026

Apr 17, 2026

H.C. Wainwright reiterates Aligos stock rating on China deal By Investing.com - Investing.com Canada

Apr 17, 2026